Immunotherapy for Melanoma Metastatic to the Brain

被引：5
|
作者：
Turajlic, Samra [1 ]
Larkin, James [2 ]
机构：
[1] Royal Marsden NHS Fdn Trust, Renal & Skin Units, London, England
[2] Francis Crick Inst, Translat Canc Therapeut Lab, London, England
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2018年 / 379卷 / 08期
关键词：
PHASE-2; TRIAL; OPEN-LABEL; THERAPY; CANCER;
D O I：
10.1056/NEJMe1807752
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：789 / 790
页数：2
相关论文
共 50 条
  • [41] Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
    Nyakas, M.
    Aamdal, E.
    Jacobsen, K. D.
    Guren, T. K.
    Aamdal, S.
    Hagene, K. T.
    Brunsvig, P.
    Yndestad, A.
    Halvorsen, B.
    Tasken, K. A.
    Aukrust, P.
    Maelandsmo, G. M.
    Ueland, T.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2019, 197 (01): : 74 - 82
  • [42] Immunotherapy in metastatic melanoma: When is it safe to stop?
    Longley, Jemma
    Paschalis, Alec
    Remer, Marcus
    Bennett, James
    Muller, Daniel R.
    Stone, Ruth
    Karydis, Ioannis
    Donnelly, Oliver
    Ottensmeier, Christian H. H.
    Wheater, Matthew James
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] IMMUNOTHERAPY WITH MONOCLONAL-ANTIBODIES IN METASTATIC MELANOMA
    STEFFENS, TA
    BAJORIN, DF
    HOUGHTON, AN
    WORLD JOURNAL OF SURGERY, 1992, 16 (02) : 261 - 269
  • [44] CONCERNING METASTATIC MELANOMA OF THE BRAIN
    KONCHAKOVA, MI
    PARSHIKOVA, SM
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 1981, 81 (07): : 1043 - 1047
  • [45] Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: Is craniotomy indicated?
    Hurst, R
    White, DE
    Heiss, J
    Lee, DS
    Rosenberg, SA
    Schwartzentruber, DJ
    JOURNAL OF IMMUNOTHERAPY, 1999, 22 (04): : 356 - 362
  • [46] ctDNA Monitoring of metastatic Melanoma patients receiving Immunotherapy
    Heidrich, I.
    Rautmann, C.
    Kott, J.
    Geidel, G.
    Ruenger, A.
    Streckenbach, A.
    Schneider, S. W.
    Pantel, K.
    Gebhardt, C.
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (03)
  • [47] Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma
    Mignard, C.
    Deschamps-Huvier, A.
    Duval-Modeste, A-B.
    Dutriaux, C.
    Khammari, A.
    Avril, M-F.
    Mortier, L.
    Lesimple, T.
    Gaudy-Marqueste, C.
    Lesage, C.
    Machet, L.
    Aubin, F.
    Meyer, N.
    Benhard, N. Beneton
    Jeudy, G.
    Montaudie, H.
    Arnault, J-P.
    Leccia, M-T.
    Joly, P.
    ANNALS OF ONCOLOGY, 2018, 29
  • [48] PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma
    Gezgin, Gulcin
    Luk, Sietse J.
    Cao, Jinfeng
    Dogrusoz, Mehmet
    van der Steen, Dirk M.
    Hagedoorn, Renate S.
    Krijgsman, Danielle
    van der Velden, Pieter A.
    Field, Matthew G.
    Luyten, Gregorius P. M.
    Szuhai, Karoly
    Harbour, J. William
    Jordanova, Ekaterina S.
    Heemskerk, Mirjam H. M.
    Jager, Martine J.
    JAMA OPHTHALMOLOGY, 2017, 135 (06) : 541 - 549
  • [49] Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma
    Zibelman, Matthew
    Olszanski, Anthony J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2014, 12 : S1 - S5
  • [50] Pronounced Thrombopenia under Immunotherapy for metastatic malignant Melanoma
    Uretzki, M.
    Boehmer, D.
    Posch, C.
    Biedermann, T.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 163 - 164
12345